Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thalidomide in agnogenic and secondary myelofibrosis.
Canepa L, Ballerini F, Varaldo R, Quintino S, Reni L, Clavio M, Miglino M, Pierri I, Gobbi M. Canepa L, et al. Among authors: ballerini f. Br J Haematol. 2001 Nov;115(2):313-5. doi: 10.1046/j.1365-2141.2001.03072.x. Br J Haematol. 2001. PMID: 11703326 Free article. Clinical Trial.
Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
Cavo M, Di Raimondo F, Zamagni E, Patriarca F, Tacchetti P, Casulli AF, Volpe S, Perrone G, Ledda A, Ceccolini M, Califano C, Bigazzi C, Offidani M, Stefani P, Ballerini F, Fiacchini M, de Vivo A, Brioli A, Tosi P, Baccarani M. Cavo M, et al. Among authors: ballerini f. J Clin Oncol. 2009 Oct 20;27(30):5001-7. doi: 10.1200/JCO.2009.22.7389. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720903
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Cavo M, et al. Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12. Blood. 2012. PMID: 22498745 Free article. Clinical Trial.
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.
Pagano L, Valentini CG, Pulsoni A, Fisogni S, Carluccio P, Mannelli F, Lunghi M, Pica G, Onida F, Cattaneo C, Piccaluga PP, Di Bona E, Todisco E, Musto P, Spadea A, D'Arco A, Pileri S, Leone G, Amadori S, Facchetti F; GIMEMA-ALWP (Gruppo Italiano Malattie EMatologiche dell'Adulto, Acute Leukemia Working Party). Pagano L, et al. Haematologica. 2013 Feb;98(2):239-46. doi: 10.3324/haematol.2012.072645. Epub 2012 Oct 12. Haematologica. 2013. PMID: 23065521 Free PMC article.
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
Zinzani PL, Pellegrini C, Merla E, Ballerini F, Fabbri A, Guarini A, Pavone V, Quintini G, Puccini B, Vigliotti ML, Stefoni V, Derenzini E, Broccoli A, Gandolfi L, Quirini F, Casadei B, Argnani L, Baccarani M. Zinzani PL, et al. Among authors: ballerini f. Hematol Oncol. 2013 Dec;31(4):179-82. doi: 10.1002/hon.2036. Epub 2012 Oct 29. Hematol Oncol. 2013. PMID: 23108928
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.
Brioli A, Perrone G, Patriarca F, Pezzi A, Nobile F, Ballerini F, Motta MR, Ronconi S, Tacchetti P, Catalano L, Zannetti BA, Rizzi S, Volpe S, Zamagni E, Liberati AM, Mancuso K, Boccadoro M, Davies FE, Morgan GJ, Palumbo A, Cavo M. Brioli A, et al. Among authors: ballerini f. Bone Marrow Transplant. 2015 May;50(5):673-8. doi: 10.1038/bmt.2014.322. Epub 2015 Feb 2. Bone Marrow Transplant. 2015. PMID: 25642764 Clinical Trial.
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.
Guolo F, Minetto P, Clavio M, Miglino M, Galaverna F, Raiola AM, Di Grazia C, Colombo N, Pozzi S, Ibatici A, Bagnasco S, Guardo D, Kunkl A, Ballerini F, Ghiggi C, Lemoli RM, Gobbi M, Bacigalupo A. Guolo F, et al. Among authors: ballerini f. Haematologica. 2017 Sep;102(9):e348-e351. doi: 10.3324/haematol.2017.167254. Epub 2017 May 11. Haematologica. 2017. PMID: 28495917 Free PMC article. No abstract available.
62 results